I am Chief of the Genitourinary Oncology Service at the Sidney Kimmel Center for Urologic and Prostate Cancers at Memorial Sloan Kettering and a board-certified medical oncologist with special expertise in treating men with advanced prostate cancer. Under my leadership, the Genitourinary Oncology Service program is dedicated to the treatment of prostate cancer, testicular cancer, bladder and upper-tract urothelial cancer, and kidney cancer. Our objective is to foster synergy between scientific research and clinical practice, and to ensure that promising scientific discoveries are used to develop new diagnostic tests and treatments for patients.
My own research is focused on three critical areas: developing treatments that target specific signaling pathways that contribute to prostate cancer growth, developing non-invasive methods to determine whether these agents are working, and improving the way drugs are evaluated in the clinic.
Targeted therapies, which attack specific cancer cells without harming normal cells, have the potential to treat cancers with fewer side effects than conventional therapies. Critical to the development of this approach, is to determine which treatment is most likely to be benefit an individual patient. Currently, prostate-specific antigen (PSA) is the best routinely available biomarker providing diagnostic and prognostic information about prostate cancer. PSA testing is useful, but does not reliably determine whether or not a treatment is working, nor does not provide definitive guidance in selecting one therapy over another. My colleagues and I are evaluating promising new technologies to capture and characterize circulating tumor cells from a routine blood draw. We are finding that the number of circulating tumor cells in a patient’s blood helps determine a patient’s prognosis and whether or not a treatment is working. Circulating tumor cells are also providing a biological snapshot of an individual patient’s tumor, which may help determine the choice of therapy.
As a member of the Prostate Cancer Clinical Trials Working Group, I led an international effort to standardize development of the design, conduct, and analysis of phase 2 clinical trials in prostate cancer, so we can better evaluate new therapeutics and assess their effectiveness using novel imaging modalities. The recommendations were incorporated and contributed to the successful development of zytiga (now approved) and enzalutamide (under review by the FDA). Both of these agents target androgen receptor signaling and were shown to prolong the survival of men with castration-resistant disease. I also developed the Clinical States Model of Prostate Cancer Progression, which, in categorizing the clinical spectrum of prostate cancer from diagnosis to metastasis, provides a framework to access and reassess a patient’s prognosis as the disease evolves over time and to guide management of the disease.
I am also the principal investigator of the Memorial Sloan Kettering Prostate Cancer SPORE (Specialized Program on Research Excellence) sponsored by the National Cancer Institute and Principal Investigator of the Prostate Cancer Clinical Trials Consortium, a 13-center research collaborative headquartered at Memorial Sloan Kettering and funded by the Department of Defense and the Prostate Cancer Foundation. A critical part of this effort is to design and conduct clinical trials of promising new approaches so that they are available to patients as soon as possible. Since 2006, the consortium has facilitated more than 120 new early-phase studies related to prostate cancer. Ultimately, through these clinical trials, we seek to develop more-effective treatments for prostate cancers of all stages and to discover means of prevention.
In addition to serving as Chief of the Genitourinary Oncology Service for the past 16 years, I am the incumbent of the D. Wayne Calloway Chair in Urologic Oncology and a Professor of Medicine at the Weill Cornell Medical College. I am a recipient of the Donald S. Coffey-Prostate Cancer Foundation Physician-Scientist Award, and the Distinguished Alumnus Award. I also serve on numerous editorial and scientific advisory boards and am a reviewer for many journals, including The New England Journal of Medicine, Nature, Science and Translational Medicine, Lancet Oncology, and the Journal of Clinical Oncology. I have written extensively and published over 430 peer-reviewed articles in scientific journals and coauthored the textbook Principals and Practice of Genitourinary Oncology.
- Clinical Expertise: Prostate Cancer and Other Genitourinary Malignancies; Immunotherapy
- Languages Spoken: English
- Education: MD, New York University School of Medicine
- Residencies: Bellevue Hospital Center (New York)
- Fellowships: Memorial Sloan Kettering Cancer Center; The New York Hospital-Cornell Medical Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Howard I. Scher
Clinical Trials Co-Investigated by Howard I. Scher
- A Phase I Study of a Vaccine-Based Immunotherapy (PrCa VBIR) for Prostate Cancer
- A Phase I Study of EC1169 in Men with Recurrent Metastatic Castration-Resistant Prostate Cancer
- A Phase I Study of ZEN003694 in Men with Advanced Prostate Cancer
- A Phase Ib Study of ARN-509 plus Everolimus in Men with Progressive Metastatic Castration-Resistant Prostate Cancer After Abiraterone Therapy
- A Phase II Study of Abiraterone Acetate without Simultaneous Prednisone in Men with Castration-Resistant Prostate Cancer, with Hormonal Assessment During Treatment
- A Phase II Study of Abiraterone with or without Cabazitaxel in Patients with Metastatic Castration-Resistance Prostate Cancer
- A Phase II Study of Degarelix plus Ipilimumab Immunotherapy with Radical Prostatectomy in Men Newly Diagnosed with Metastatic Prostate Cancer
- A Phase III Study of ARN-509 versus Placebo in Men with Non-Metastatic Castration-Resistant Prostate Cancer
- Adoptive Transfer of Autologous T Cells Targeted to Prostate-Specific Membrane Antigen for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Development of Molecular Predictors to Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
- [18F]-Deoxy-D-Glucose (FDG) and [18F] Dihydro-Testosterone PET Imaging in Patients with Progressive Prostate Cancer
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more